Prevalence of PALB2 mutations in the Creighton University Breast Cancer Family Registry

Breast Cancer Research and Treatment
C SnyderHenry T Lynch

Abstract

The purpose of this study is to determine the prevalence of PALB2 mutations among breast cancer families from the United States. The PALB2 gene was screened for mutations in 90 familial breast cancer patients from the Creighton University Breast Cancer Family Registry. These patients had previously tested negative for mutations in BRCA1 and BRCA2. Two of 90 breast cancer patients (2.2 %) were found to carry a truncating mutation in PALB2 (c.2411_2412delCT and c.2053delC). Both probands were diagnosed with breast cancer before age 35 and each had three relatives with breast cancer. Mutations in PALB2 are less common than BRCA1 and BRCA2 in familial breast cancer patients. However, testing for PALB2 mutations is a useful adjunct for patients undergoing testing for BRCA1 and BRCA2.

References

Feb 9, 2007·Nature·Hannele ErkkoRobert Winqvist
May 20, 2009·Bioinformatics·Heng Li, Richard Durbin
Feb 4, 2010·BMC Medical Genetics·Agnieszka Dansonka-MieszkowskaJolanta Kupryjanczyk
Dec 25, 2010·Breast Cancer Research : BCR·Melissa C SoutheyUNKNOWN kConFab for the Beast Cancer Family Registry
Aug 8, 2014·The New England Journal of Medicine·Antonis C AntoniouMarc Tischkowitz
Oct 23, 2014·The New England Journal of Medicine·Antonis C AntoniouMarc Tischkowitz
Oct 23, 2014·The New England Journal of Medicine·Ann S G Lee, Peter Ang
Oct 31, 2014·Genetics in Medicine : Official Journal of the American College of Medical Genetics·David B ZhenGloria M Petersen
Jan 13, 2015·Breast Cancer Research and Treatment·Tú Nguyen-DumontMelissa C Southey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.

Related Papers

Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
Chuan-gui SongZhi-min Shao
European Journal of Gynaecological Oncology
J MenkiszakJan Lubinski
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology
F J CouchRalph H Hruban
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Helen A ShihBarbara L Weber
© 2021 Meta ULC. All rights reserved